[高血症管理有什么新鲜事?]
F Lefevre1, C Mousseaux2, M Bobot3
1Centre de néphrologie et transplantation rénale, hôpital de la Conception, AP-HM, 147, boulevard Baille, 13005 Marseille, France.
La Revue de medecine interne
|January 14, 2024
概括
对患有慢性脏病的患者和服用氨酸-氨酸-阿尔多素系统抑制剂的患者来说,高血症的管理至关重要. 新的治疗方法提供了替代方案,但它们的长期疗效和安全性需要进一步研究.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 内部医学 内部医学
- 临床药理学 临床药理学
背景情况:
- 高血是常见且严重的疾病,特别是在慢性病 (CKD) 或接受氨酸-氨酸-阿尔多斯特系统抑制剂 (iRAAS) 治疗的患者中.
- 有效地管理高血症对于预防死亡率和避免中断重要的心脏和脏保护疗法,如iRAAS,至关重要.
- 目前的治疗选择,如聚二烯硫酸盐,面临着患者接受度和安全性方面的挑战.
研究的目的:
- 审查当前高卡利米亚管理的现状.
- 评估新兴结合剂及其在临床实践中的潜在作用.
- 讨论辅助疗法和需要基于证据的治疗指南.
主要方法:
- 临床研究的文献综述和高血症管理指南.
- 对现有和新型降剂的安全性和疗效数据的分析.
- 在常见的并发症和同时服用药物的背景下讨论治疗策略.
主要成果:
- 聚二烯硫酸盐的使用受限于耐受性问题和最近的安全问题.
- 新的结合剂,帕特和硫酸可用,但需要进一步评估长期使用和可接受性.
- 组合疗法,包括 thiazide 利尿剂或与 iRAAS 结合的 SGLT2 抑制剂,在慢性病患者中显示出对卡莱米亚控制的前景.
结论:
- 需要对各种低血压治疗的定位做出明确的建议.
- 治疗选择应根据患者的并发症和所选药物的更广泛的药理作用进行个性化选择.
- 需要进一步的研究来确定新型高血症治疗的长期疗效,安全性和患者报告的结果.
相关概念视频
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
563
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
563
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.0K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.0K
01:26Heart Failure Drugs: Inotropic Agents
591
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
746
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
746
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
01:22Heart Failure Drugs: Diuretics
384
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
384